tci Part B Insider - 2006 Issue 25
ONCOLOGY: Make Your Voice Heard Now To Prevent Steep Drug Cuts
Oncology drugs overpriced by as much as 185 percentFive commonly billed oncology drugs are at least 5 percent cheaper than the prices Medicare pays physicians for them, the HHS Office of Inspector General claims in a new survey. The OIG claims that carboplatin (J9045) is overpriced by a startling 185.1 percent, dexamethasone sodium phosphate (J1100) is overvalued by 65.2 percent, and dolasetron mesylate (J1260) is 55.6 percent too expensive. The survey found two other drugs, vinorelbine tartrate (J9390) and granisetron HCI (J1626), also had double-digit overpayments.The drugs were overpriced for a number of reasons, including...
To read the full article, sign in and subscribe to tci Part B Insider.
Thank you for choosing Find-A-Code, please Sign In to remove ads.